Patent & IP news for October 6, 2017

Patent Litigations

  • No new litigations this day!

USPTO Weekly Stats

9,645
published
appl'ns
7,218
granted
patents
64
ptab
decisions

Patent & IP Blogs

post image Federal Circuit: Antibody-Exception to Written Description Does Not Exist from patentlyo.com

By Dennis Crouch Amgen v. Sanofi (Fed. Cir. 2017).  The Delaware district court sided with Patentee Amgen and awarded permanent injunctive relief barring Sanofi from selling its injectable drug product Praulent (alirocaumab) – a human monoclonal ...

Share via E–mail | Twitter | Facebook

New WIPO External Auditor, Officers; Vietnam To Chair Assembly; New Treaty Accessions from www.ip-watch.org

At the start of the World Intellectual Property Organization General Assembly this week, officers to chair the assemblies of WIPO-managed unions were elected. Following a change of rule last year, a chair was also elected ...

Share via E–mail | Twitter | Facebook

Asia Pacific Countries Challenge Composition Of WIPO Program And Budget Committee from www.ip-watch.org

The World Intellectual Property Organization Program and Budget Committee is arguably the most powerful committee of the United Nations agency, and is open to a limited number of countries. This year, the countries sitting on ...

Share via E–mail | Twitter | Facebook

The Imminent Problem of Counterfeit Sports Merchandise from www.iposgoode.ca

Counterfeit products are a growing issue and have resulted in an annual estimated loss of $20-30 billion in tax revenue for Canada over the past few years. In particular, the rise in counterfeit sports merchandise ...

Share via E–mail | Twitter | Facebook

A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents from patentlyo.com

My Senator (McCaskill) has introduced S. 1948 titled “A bill to abrogate the sovereign immunity of Indian tribes as a defense in inter partes review of patents.”  [TribalImmunity] The Bill provides one simple statement as ...

Share via E–mail | Twitter | Facebook

Functional Claiming of Antibodies: (Continue to) Proceed With Caution from www.orangebookblog.com

CAFC holds that later-developed antibody species may be evidence that a claimed antibody genus is invalid for lack of written description, and casts doubt on the “antibody exception” Amgen Inc. v. Sanofi, No. 2017-1480 (Fed ...

Share via E–mail | Twitter | Facebook

Some content © 2007–2017 RPX Corporation.
Terms of Service & Privacy Policy
For DMCA requests contact help@priorsmart.com.